EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities

Matthew Ho iD, Saurabh Zanwar iD, Jonas Paludo iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14074 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Matthew Ho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Lymphoma, Non-Hodgkin, Multiple Myeloma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 137 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success of chimeric antigen receptor T‐cell (CAR‐T) therapy in hematologic malignancies has realized a longstanding effort toward harnessing the immune system to fight cancer in a truly personalized fashion. Second generation chimeric antigen receptors (CAR) incorporating co‐stimulatory molecules like 4‐1BB or CD28 were able to overcome some of the hindrances with initial CAR constructs resulting in efficacious products. Many second‐generation CAR‐T products have been approved in the treatment of relapsed/refractory hematologic malignancies including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia. However, challenges remain in optimizing the manufacturing, timely access, limiting the toxicity from CAR‐T infusions and improving sustainability of responses derived with CAR‐T therapy. Here, we summarize the clinical trial data leading to approval CAR‐T therapies in MM and NHL, discuss the limitations with current CAR‐T therapy strategies and review emerging strategies for overcoming these limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematologic NeoplasmsLymphoma, Non-HodgkinMultiple MyelomaHumansImmunotherapy, AdoptiveRecurrenceCell- and Tissue-Based TherapyReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR-Tchimeric antigencytokine releaselymphomamyelomarelapsed refractory

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Matthew Ho, Saurabh Zanwar, Jonas Paludo

Zitieren

APA

Ho, M., Zanwar, S., & Paludo, J. (2024). Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities. European Journal of Haematology. https://doi.org/10.1111/ejh.14074

Vancouver

Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities. European Journal of Haematology. 2024. doi:10.1111/ejh.14074

BibTeX
@article{Ho2024,
  author = {Ho, Matthew and Zanwar, Saurabh and Paludo, Jonas},
  title = {Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14074}
}
Kostenlos starten →